LeMaitre Vascular’s (LMAT) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report released on Friday morning, Benzinga reports. The firm currently has a $93.00 target price on the medical instruments supplier’s stock, up from their previous target price of $90.00.

LMAT has been the topic of several other research reports. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. JMP Securities increased their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Finally, Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Up 7.3 %

LMAT opened at $94.88 on Friday. LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $101.67. The company has a market cap of $2.13 billion, a P/E ratio of 51.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89. The firm’s 50-day moving average price is $89.59 and its 200-day moving average price is $83.25.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. On average, research analysts anticipate that LeMaitre Vascular will post 1.86 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.67%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LMAT. Driehaus Capital Management LLC lifted its position in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares in the last quarter. F M Investments LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $7,443,000. Nicholas Investment Partners LP purchased a new position in LeMaitre Vascular in the 2nd quarter valued at $3,900,000. Janus Henderson Group PLC lifted its holdings in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after purchasing an additional 47,218 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after purchasing an additional 38,303 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.